Last reviewed · How we verify
Botulinum toxin A 150u
Botulinum toxin A 150u is a Neurotoxin; Acetylcholine release inhibitor Small molecule drug developed by EvergreenHealth. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: BOTOX®, OnabotulinumtoxinA.
Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botulinum toxin A 150u |
|---|---|
| Also known as | BOTOX®, OnabotulinumtoxinA |
| Sponsor | EvergreenHealth |
| Drug class | Neurotoxin; Acetylcholine release inhibitor |
| Target | SNARE proteins (specifically SNAP-25) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Dermatology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin A is a neurotoxin that irreversibly cleaves SNARE (soluble N-ethylmaleimide-sensitive factor attachment receptor) proteins required for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Hyperhidrosis
- Spasticity
- Facial wrinkles (cosmetic)
Common side effects
- Headache
- Neck pain
- Muscle weakness
- Injection site pain
- Flu-like symptoms
- Eyelid ptosis
- Diplopia
Key clinical trials
- A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity (PHASE1, PHASE2)
- A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction (PHASE4)
- Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence (PHASE3)
- Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin A 150u CI brief — competitive landscape report
- Botulinum toxin A 150u updates RSS · CI watch RSS
- EvergreenHealth portfolio CI
Frequently asked questions about Botulinum toxin A 150u
What is Botulinum toxin A 150u?
How does Botulinum toxin A 150u work?
What is Botulinum toxin A 150u used for?
Who makes Botulinum toxin A 150u?
Is Botulinum toxin A 150u also known as anything else?
What drug class is Botulinum toxin A 150u in?
What development phase is Botulinum toxin A 150u in?
What are the side effects of Botulinum toxin A 150u?
What does Botulinum toxin A 150u target?
Related
- Drug class: All Neurotoxin; Acetylcholine release inhibitor drugs
- Target: All drugs targeting SNARE proteins (specifically SNAP-25)
- Manufacturer: EvergreenHealth — full pipeline
- Therapeutic area: All drugs in Neurology; Dermatology; Aesthetics
- Indication: Drugs for Cervical dystonia
- Indication: Drugs for Blepharospasm
- Indication: Drugs for Strabismus
- Also known as: BOTOX®, OnabotulinumtoxinA
- Compare: Botulinum toxin A 150u vs similar drugs
- Pricing: Botulinum toxin A 150u cost, discount & access